Evidence map›Paper›PMID 40492974›Full record

ArticleACS chemical biology2025

High-Throughput Screening Tool to Identify Small Molecule Inhibitors of Telomerase.

Elisa Aquilanti, Sulyman Barkho, Vincent Bozinov, Lauren Kageler, Max Garrity-Janger, Michael F Mesleh, Steven Horner, Matthew J Ranaghan, Matthew Meyerson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elisa AquilantiDivision of Neuro Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, United States.ORCID 0000-0002-1343-5017
Sulyman BarkhoCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Vincent BozinovCancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Lauren KagelerStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts 02115, United States.
Max Garrity-JangerCancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Michael F MeslehCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Steven HornerCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Matthew J RanaghanCenter for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.
Matthew MeyersonCancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States.

Funding

Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
NKX2-1 Enhancer Amplification and Lineage Addiction in Lung AdenocarcinomaR35CA197568 · NCI · DANA-FARBER CANCER INST · PI Matthew L. Meyerson · 2015 to 2026
$12.4M
NCI NIH HHS R35 CA197568NCI NIH HHS T32 CA009172
6 · The paper itself

Abstract

Telomerase reverse transcriptase is a ribonucleoprotein complex that maintains telomere length in rapidly dividing cells, thus enabling cellular immortality. Despite being recognized as an important cancer target for decades, no small molecule telomerase inhibitors have been approved as anticancer therapeutics to date. Several limitations, including the absence of high-throughput screening tools, have posed challenges to the telomerase drug discovery field. Here, we describe a high-throughput, fluorescently coupled screening method employing a chemically modified reporter nucleotide. We utilize the

Indexed as

Enzyme InhibitorsHigh-Throughput Screening AssaysSmall Molecule LibrariesTelomeraseAnimalsDrug DiscoveryHumansTriboliumEnzyme InhibitorsSmall Molecule LibrariesTelomerase

Identifiers

PMID40492974
PMCPMC12281481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.